Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAF1 | P21675 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 3/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22927192 | 0.88 | PTGER4 (0.38) | TAF1CECR2BRD9CD38BTK | |
| SCHEMBL26432933 | 0.86 | TAF1 (0.39) | TAF1CECR2BRD9CD38BTK | |
| SCHEMBL21506647 | 0.83 | P2RX7 (0.39) | TAF1CECR2BRD9BTKKMT2A | |
| SCHEMBL21506731 | 0.76 | TAF1 (0.42) | TAF1CECR2BRD9CD38BTK | |
| SCHEMBL21481820 | 0.76 | TAF1 (0.42) | TAF1CECR2BRD9CD38BTK | |
| SCHEMBL21506745 | 0.74 | TNF (0.38) | TNFIRAK4KMT2AEZH2EGFR | |
| SCHEMBL31203605 | 0.71 | PIM3 (0.47) | BTKP2RX7 | |
| SCHEMBL5258354 | 0.71 | PIM3 (0.47) | BTKP2RX7 | |
| SCHEMBL24991863 | 0.71 | CNR2 (0.41) | TNFIRAK4EGFR | |
| SCHEMBL21458334 | 0.71 | CNR2 (0.36) | TNFIRAK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | TAF1 4299/4885CECR2 390/4885BRD9 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.